BridgeBio director receives new RSU and option grants

BridgeBio Pharma director Fred Hassan reported new equity awards in the form of stock units and options.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma director Fred Hassan reported new equity awards in the form of stock units and options. He received 3,990 restricted stock units, each representing one future share of common stock, bringing his direct common share holdings to 29,879 after the grant.

Hassan was also granted options covering 5,277 shares of common stock at an exercise price of $68.92 per share. Both the RSUs and the option shares vest in full on June 22, 2027, conditioned on his continued service on BridgeBio’s board of directors through that date. The stock options expire on June 21, 2036.

Insider Trade Summary

Grant/Award: 9,267 shares

Grant/Award 2 txns

Insider Hassan Fred

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,277	$0.00	$0.00
Grant/Award	Common Stock	3,990	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,277 contracts (Direct); Common Stock — 29,879 shares (Direct)

Footnotes (3)

F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Key Figures

RSU grant size: 3,990 units Shares held after RSU grant: 29,879 shares Option grant size: 5,277 options +4 more

7 metrics

RSU grant size 3,990 units Restricted stock units granted June 22, 2026

Shares held after RSU grant 29,879 shares Common stock directly held after award

Option grant size 5,277 options Stock options granted June 22, 2026

Option exercise price $68.92 per share Stock Option (Right to Buy) exercise price

Option expiration June 21, 2036 Expiration date of stock options

RSU vesting date June 22, 2027 RSUs vest in full on this date

Option vesting date June 22, 2027 Options vest in full on this date

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan, vest in full, +1 more

5 terms

restricted stock units ("RSUs") financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with 5,277.0000 shares at an exercise price of 68.9200."

2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

vest in full financial

"The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Fred Hassan receive from BridgeBio Pharma (BBIO)?

Fred Hassan received 3,990 restricted stock units and stock options for 5,277 shares of BridgeBio Pharma common stock. These awards are part of his director compensation and give him rights to future shares, subject to vesting conditions and continued board service.

When do Fred Hassan’s new BridgeBio Pharma (BBIO) RSUs and options vest?

Both Fred Hassan’s 3,990 restricted stock units and his options for 5,277 underlying shares vest in full on June 22, 2027. Vesting requires his continued service on BridgeBio Pharma’s board of directors through that vesting date, according to the grant terms.

What is the exercise price and expiration date of Fred Hassan’s BridgeBio (BBIO) stock options?

Fred Hassan’s newly granted stock options have an exercise price of $68.92 per share and expire on June 21, 2036. They cover 5,277 underlying common shares and vest in full on June 22, 2027, assuming continued board service through that date.

How many BridgeBio Pharma (BBIO) shares does Fred Hassan hold after these grants?

After receiving 3,990 restricted stock units, Fred Hassan’s direct common stock holdings total 29,879 shares. In addition, he holds options covering 5,277 underlying shares, which will become exercisable after vesting on June 22, 2027, if conditions are satisfied.

Are Fred Hassan’s new BridgeBio (BBIO) awards open-market purchases or compensation grants?

The reported transactions are compensation-related grants, not open-market purchases. They consist of restricted stock units and stock options awarded under BridgeBio Pharma’s 2021 Amended and Restated Stock Option and Incentive Plan, with zero-dollar grant prices and specified vesting schedules.

What plan governs Fred Hassan’s new BridgeBio Pharma (BBIO) RSU grant?

Fred Hassan’s 3,990 restricted stock units were granted under BridgeBio Pharma’s 2021 Amended and Restated Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of common stock, vesting in full on June 22, 2027, subject to continued board service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/24/2026 - 06:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hassan Fred

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/22/2026		A⁽¹⁾		3,990	A	$0⁽²⁾	29,879	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$68.92	06/22/2026		A		5,277		⁽³⁾	06/21/2036	Common Stock	5,277	$0	5,277	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Will Solis, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR